Coronary Stents Market Worldwide Holds Big Incentive for Growth, Opportunity in Novel Technologies

PRLog (Press Release) - May 19, 2009 -
The market for coronary stents is, in many ways, still emerging. While coronary stents have been on the commercial market in one form or another for several years, the technologies and materials used to create the devices are improving every day. In addition, innovative technology is bringing new classes of devices (e.g., fully degradable stents) to market, technologies that grow the market and even expand stent therapy to new patient populations in some cases. The market for coronary stents into four primary categories: drug-eluting stents (DES), bare metal stents (BMS), absorbables, and "others", which include bioactive, radioactive and drug-eluting balloons. The worldwide coronary stents market is analyzed in a new report from MedMarket Diligence, LLC.

"The coronary stent market remains a vibrant device sector with market growth and the number of current and hopeful competitors," says Patrick Driscoll, President of MedMarket Diligence. According to Driscoll, over 75 companies are active in the field of coronary stents, spanning the full range of stent designs. While the market is dominated by early players J&J and Boston Scientific, other major device companies - Medtronic and Abbott Vascular - are gaining significant shares of these markets, while the size and growth of the market provides ample incentive for many smaller companies to vie for positions.

Currently, market penetration for DES devices ranges in the neighborhood of 60% (as high as 90% in China) and is growing at more than 7% per year worldwide. By comparison, the worldwide market for all coronary stents is currently growing at nearly 6% while the market for bare metal stents is growing at 3% per year. Compounded annually from 2008 to 2017, the market for all currently available coronary stents is growing most strongly for drug-eluting stents, followed by bare metal stents. However, during this forecast period, the emergence (and approval) of bioabsorbable and other novel stent types will result in dramatically better growth than even drug-eluting stents.

The MedMarket Diligence report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017," details the worldwide market for the use of coronary stents in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types. The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

The report, published May 2009, is detailed at http://www.mediligence.com/rpt/rpt-c245.htm.

The report may be ordered for immediate download (and with a limited time discount) online at http://www.mediligence.com/store/page30.html or may be ordered via order form, http://www.mediligence.com/order_forms/c245_order.pdf.